APA (7th ed.) Citation

Duska, L., Krasner, C., O'Malley, D., Hays, J., Modesitt, S., Mathews, C., . . . Schilder, R. (2021). A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecologic Oncology, 160(3), 688. https://doi.org/10.1016/j.ygyno.2020.12.025

Chicago Style (17th ed.) Citation

Duska, L.R, et al. "A Phase Ib/II and Pharmacokinetic Study of EP0057 (formerly CRLX101) in Combination with Weekly Paclitaxel in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer." Gynecologic Oncology 160, no. 3 (2021): 688. https://doi.org/10.1016/j.ygyno.2020.12.025.

MLA (9th ed.) Citation

Duska, L.R, et al. "A Phase Ib/II and Pharmacokinetic Study of EP0057 (formerly CRLX101) in Combination with Weekly Paclitaxel in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer." Gynecologic Oncology, vol. 160, no. 3, 2021, p. 688, https://doi.org/10.1016/j.ygyno.2020.12.025.